L-Arginine Increases Postprandial Circulating GLP-1 and PYY Levels in Humans

Obesity (Silver Spring). 2018 Nov;26(11):1721-1726. doi: 10.1002/oby.22323.

Abstract

Objective: The satiating effect of protein compared with other nutrients has been well described and is thought to be mediated, in part, by gut hormone release. Previously, it has been shown that oral L-arginine acts as a GLP-1 secretagogue both in vitro and in vivo in rodents. Here, the effect of L-arginine on gut hormone release in humans was investigated.

Methods: The hypothesis was tested in two separate studies. The first study assessed the tolerability of oral L-arginine in healthy human subjects. The second study assessed the effect of oral L-arginine on gut hormone release following an ad libitum meal. Subjects were given L-arginine, glycine (control amino acid), or vehicle control in a randomized double-blind fashion.

Results: At a dose of 17.1 mmol, L-arginine was well tolerated and stimulated the release of plasma GLP-1 (P < 0.05) and PYY (P < 0.001) following an ad libitum meal. Food diaries showed a trend toward lower energy intake and particularly fat intake following L-arginine treatment.

Conclusions: L-arginine can significantly elevate GLP-1 and PYY in healthy human volunteers in combination with a meal. Further work is required to investigate whether L-arginine may have utility in the suppression of appetite and food intake.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Appetite Depressants / pharmacology
  • Appetite Depressants / therapeutic use*
  • Arginine / pharmacology
  • Arginine / therapeutic use*
  • Double-Blind Method
  • Eating / drug effects*
  • Female
  • Glucagon-Like Peptide 1 / blood
  • Glucagon-Like Peptide 1 / drug effects*
  • Humans
  • Male
  • Peptide YY / blood
  • Peptide YY / drug effects*
  • Postprandial Period / drug effects*

Substances

  • Appetite Depressants
  • Peptide YY
  • Glucagon-Like Peptide 1
  • Arginine